Klaus ZÃ¶phel

List of Publications by Year
in descending order

Version: 2024-02-01

30 papers	783 citations	623734 14 h-index	526287 27 g-index
33 all docs	33 docs citations	33 times ranked	1399 citing authors

#	Article	IF	Citations
1	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. Scientific Reports, 2017, 7, 13206.	3.3	163
2	Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. Radiotherapy and Oncology, 2017, 124, 533-540.	0.6	123
3	Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma. Journal of Nuclear Medicine, 2015, 56, 1150-1156.	5.0	59
4	CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer. Radiotherapy and Oncology, 2019, 130, 10-17.	0.6	44
5	Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. Radiotherapy and Oncology, 2020, 149, 189-196.	0.6	41
6	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. European Urology, 2019, 75, 548-551.	1.9	36
7	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiation Oncology, 2018, 13, 90.	2.7	34
8	Holmium-166 Radioembolization in Hepatocellular Carcinoma: Feasibility and Safety of a New Treatment Option in Clinical Practice. CardioVascular and Interventional Radiology, 2019, 42, 405-412.	2.0	34
9	Intraindividual comparison of [68ÂGa]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Research, 2021, 11, 109.	2.5	32
10	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomographyâ€“staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. European Urology Oncology, 2022, 5, 44-51.	5.4	26
11	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. Radiotherapy and Oncology, 2019, 135, 43-50.	0.6	25
12	Dualâ€timeâ€point ⁶⁴<scp>Cuâ€PSMA</scp>â€617â€<scp>PET/CT</scp> in patients suffering from prostate cancer. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 523-532.	1.0	22
13	Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 1-23.	2.0	16
14	PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings. Case Reports in Urology, 2017, 2017, 1-3.	0.3	15
15	Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma. Clinical Cancer Research, 2021, 27, 1351-1360.	7.0	15
16	FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. Radiotherapy and Oncology, 2019, 130, 97-103.	0.6	14
17	Prostate-specific Membrane Antigen-targeted Ligand Positron Emission Tomography/Computed Tomography and Immunohistochemical Findings in a Patient With Synchronous Metastatic Penile and Prostate Cancer. Urology, 2017, 101, e5-e6.	1.0	11
18	[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. EJNMMI Research, 2020, 10, 135.	2.5	11

#	Article	IF	Citations
19	FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy. Radiotherapy and Oncology, 2017, 122, 437-444.	0.6	10
20	ï»¿68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients. Nuklearmedizin - NuclearMedicine, 2019, 58, 352-362.	0.7	9
21	Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients. Clinical and Translational Radiation Oncology, 2019, 15, 108-112.	1.7	9
22	Splenunculus Masquerading as Prostate-specific Membrane Antigen-positive Lymph Node Metastasis in a Patient With Prostate-specific Antigen Relapse After Radical Prostatectomy. Urology, 2016, 94, e1-e2.	1.0	8
23	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). Cancers, 2022, 14, 2073.	3.7	7
24	A novel third-generation TSH receptor antibody (TRAb) enzyme-linked immunosorbent assay based on a murine monoclonal TSH receptor-binding antibody. Immunologic Research, 2018, 66, 768-776.	2.9	6
25	Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer. Radiotherapy and Oncology, 2021, 155, 204-211.	0.6	5
26	Comparison of subjective evaluation versus objective algorithm in the interpretation of follow-up FDG-PET/CT scans after radiochemotherapy in head and neck cancer patients. Nuklearmedizin - NuclearMedicine, 2019, 58, 93-100.	0.7	3
27	Third generation radioimmunoassay (RIA) for TSH receptor autoantibodies (TRAb) â€“ one step less, similar results?. Nuklearmedizin - NuclearMedicine, 2021, 60, 38-46.	0.7	2
28	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.7	2
29	Editorial: Listen to your belly, fat is not your foe!. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 108-109.	6.4	0
30	Fluorodeoxyglucose-positive Splenic Infarctions are Completely Regressive Just after 4 Months. Indian Journal of Nuclear Medicine, 2018, 33, 239-241.	0.3	0